ObjectiveTo investigate the influence on efficacy and quality of life of amisulpride in schizophrenia with predominantly negative symptoms.MethodsSeventy cases of schizophrenia with predominantly negative symptoms were randomly assigned to amisulpride group and clozapine group for 12weeks.The clinical efficacy and side effects were evaluated with SANS,BPRS and TESS before and 1,2,4,8,12 weeks after treatment respectively. GQOLI-74 were used to evaluate the patients' quality of life before and after drug administration.ResultsFor the last assessment,the score of BPRS decrease to 30.68 ±4.62 in amisulpride group,was significantly lower than the beginning(P＜0.01 ) ; the score of BPRS decrease to 31.31 ±4.78 in clozapine group,was significantly lower than the beginning (P ＜ 0.01 ).Two groups showed similar effects,with no significance.12weeks after treatment,the scores of emotional dull,poverty of thought,volition abulia,interest-social lack,attention dysfunction in amisulpride group were 12.31 ± 4.43,9.66 ± 3.07,8.91 ± 2.56,10.29 ± 2.68,5.58 ± 1.43 ; and the scores of emotional dull,poverty of thought,volition abulia,interest-social lack,attention dysfunction in clozapine group were 14.62 ± 4.27,9.32 ± 2.81,8.22 ± 2.60,9.54 ± 2.67,6.62 ± 1.59,and the efficacy of amisulpride in emotional dull and attention dysfunction were better than those of clozapine.And the scores of material life,physical function,psychological function,social function in amisulpride group were not higher than those in clozapine group(P＞ 0.05).And the scores of four domains in GQOLI-74 had been improved significantly in two groups(P＜0.01).The domains of physical function,psychological function,and social function in amisulpride was superior to clozapine(P＜0.01).The side effects were more in clozapine group than those in amisulpride group.ConclusionAmisulpride is as effective as clozapine for the treatment of schizophrenia with predominantly negative symptoms,but it has more advantage than clozapine to improve emotional dull,attention dysfunction and quality of life in schizophrenia with predominantly negative symptoms.

Objective This study aimed to compare the motor behavior and pathological changes of YG8R transgenic mouse models of Friedreich ataxia (FRDA). Methods The movement behavior changes between YG8R mice and littermate wild-type (WT) mice were evaluated by the accelerated rotarod test,open field test,grip strength test and gait analysis. Real-time fluorescence-based quantitative PCR (qRT-PCR) was used to detect the Frataxin mRNA in the dorsal root ganglia (DRG) and cerebellum. Immunohistochemical staining was used to evaluate neuronal death in the mouse spinal cord tissue. Results Compared with WT mice,the time-to-fall off on an accelerating rotarod,movement distance,and grip strength of YG8R mice were significantly decreased (P<0.05) from 4 to 6 months. Compared to WT mice,YG8R mice had significantly decreased left and right hindlimb step lengths (P<0.05),increased forelimb and hindlimb step widths (P<0.01),decreased right hind limb swing time (P<0.01),and increased the touchdown time of the left and right hind limbs (P<0.05). The number of neurons in the spinal cord of YG8R mice was significantly decreased (P<0.01). The qRT-PCR results showed that frataxin mRNA levels in the spinal cord and DRG of YG8R mice were significantly decreased compared with the WT group (P<0.0001). Conclusion This study further provides detailed motor characteristics and pathological changes of the YG8R transgenic mouse models of FRDA based on GAA repeat expansion,which will be helpful for follow-up studies on the disease mechanism and treatment of FRDA.